



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 8174

SERIAL NUMBER	FILING OR 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
09/716,356	11/21/2000 RULE	514	1648	USHIO-2

## APPLICANTS

Shimpei Ushio, Okayama, JAPAN;  
 Kakuji Torigoe, Kurashiki-shi, JAPAN;  
 Tadao Tanimoto, Okayama, JAPAN;  
 Haruki Okamura, Osaka, JAPAN;  
 Masashi Kurimoto, Okayama, JAPAN;  
 Shigeharu Fukuda, Okayama, JAPAN;  
 Toshio Kunikata, Okayama, JAPAN;  
 Mutsuko Taniguchi, Okayama, JAPAN;  
 Keizo Kohno, Okayama, JAPAN;

## \*\* CONTINUING DATA \*\*\*\*\*

This application is a CIP of 08/832,180 04/08/1997 PAT 6,214,584 which is a DIV of 08/558,191 11/15/1995 ABN

This application 09/716,356

is a CIP of 08/974,469 11/20/1997 PAT 6,207,641

which is a CON of 08/599,879 02/14/1996 ABN

which is a CIP of 08/558,190 11/15/1995 ABN

This application 09/716,356

is a CIP of 08/558,818 11/15/1995 PAT 6,197,297

and is a CIP of 08/832,177 04/08/1997 PAT 6,268,486

which is a DIV of 08/558,818 11/15/1995 PAT 6,197,297

This application 09/716,356

is a CIP of 08/832,198 04/08/1997 PAT 6,242,255

which is a DIV of 08/721,018 09/26/1996 ABN

## \*\* FOREIGN APPLICATIONS \*\*\*\*\*

## IF REQUIRED, FOREIGN FILING LICENSE GRANTED

\*\* 02/14/2001

Foreign Priority claimed	<input type="checkbox"/> yes <input checked="" type="checkbox"/> no	STATE OR COUNTRY	SHEETS DRAWING	TOTAL CLAIMS	INDEPENDENT CLAIMS
35 USC 119 (a-d) conditions met	<input type="checkbox"/> yes <input checked="" type="checkbox"/> no <input type="checkbox"/> Met after Allowance	JAPAN	5	20	3
Verified and Acknowledged	Examiner's Signature <i>[Signature]</i> Initials <i>2L</i>				

## ADDRESS

001444

## TITLE

INTERFERON -Y INDUCING POLYPEPTIDE, PHARMACEUTICAL COMPOSITION THEREOF,  
 MONOCLONAL ANTIBODY THERETO, AND METHODS OF USE

☐ All Fees